Epernicus: Hermann A. M. Mucke, Ph.D.

Hermann A. M. Mucke, Ph.D.

Position:
Pharmacology consultant

H.M. Pharma Consultancy
Degrees:

Ph.D., Biochemistry, University of Vienna (Vienna, Austria)

M.Sc., Molecular Biology, University of Vienna (Vienna, Austria)
Past Advisors:
Research:
Other Experience:
2000-present Independent consultant operating H.M. Pharma Consultancy

Communities:

Hermann Mucke's Genealogy

The Adobe Flash Player plugin (version 8) is required to view the genealogy tree.
Download the plugin here.

Hermann Mucke's Publications (25)

PHup2DATE 2010: Guideline-compliant diagnosis and therapy of pulmonary hypertension. 6 March 2010, Munich, Germany.
Mucke HA

IDrugs : the investigational drugs journal. 2010 May;13(5):308-10
Current drug patenting for retinal diseases: beyond VEGF inhibitors.
Mucke HA, Mucke PM

IDrugs : the investigational drugs journal. 2010 Jan;13(1):30-7
Randomized, crossover, single-blind, placebo-controlled, human pharmacology clinical trial with desoxypeganine, a new cholinesterase and selective MAO-A inhibitor: multiple-dose pharmacokinetics.
Algorta J, Pena MA, Alvarez A, Maraschiello C, Maruhn D, Windisch M, Mucke HA

International journal of clinical pharmacology and therapeutics. 2009 Jul;47(7):483-90
Small-molecule endothelin receptor antagonists: a review of patenting activity across therapeutic areas.
Mucke HA

IDrugs : the investigational drugs journal. 2009 Jun;12(6):366-75
International patenting in ophthalmology: An analysis of its structure and relevance for the development of drugs and diagnostics.
Mucke HA, Mucke P, Mucke E

Clinical ophthalmology (Auckland, N.Z.). 2009;3:103-9
Pulmonary arterial hypertension: on the way to a manageable disease.
Mucke HA

Current opinion in investigational drugs (London, England : 2000). 2008 Sep;9(9):957-62
Phase I clinical trial with desoxypeganine, a new cholinesterase and selective MAO-A inhibitor: tolerance and pharmacokinetics study of escalating single oral doses.
Algorta J, Pena MA, Maraschiello C, Alvarez-González A, Maruhn D, Windisch M, Mucke HA

Methods and findings in experimental and clinical pharmacology. 2008 Mar;30(2):141-7
Cardiovascular developments: patent highlights July to December 2006.
Mucke HA

Current opinion in investigational drugs (London, England : 2000). 2007 Mar;8(3):193-200
New ocular therapeutics: a view from the patenting perspective.
Mucke HA

IDrugs : the investigational drugs journal. 2007 Jan;10(1):37-41
Cardiovascular and renal developments: patent highlights January to June 2006.
Mucke HA

Current opinion in investigational drugs (London, England : 2000). 2006 Sep;7(9):792-8
Data from the VITA Study do not support the concept of vascular depression.
Rainer MK, Mucke HA, Zehetmayer S, Krampla W, Kuselbauer T, Weissgram S, Jungwirth S, Tragl KH, Fischer P

The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry. 2006 Jun;14(6):531-7
Genomics-based cardiovascular drug development: the challenges are just beginning.
Mucke HA

Current opinion in investigational drugs (London, England : 2000). 2006 Mar;7(3):203-5
The failing heart as a drug target: are we finally seeing progress?
Mucke HA

Current opinion in investigational drugs (London, England : 2000). 2005 Sep;6(9):870-3
[State of the art management of BPSD in dementia]
Rainer MK, Mucke HA, Masching AJ, Haushofer M, Karger M, Kasper S, Kurz A

Psychiatrische Praxis. 2005 Jan;32(1):31-8
Zotepine for behavioural and psychological symptoms in dementia: an open-label study.
Rainer MK, Mucke HA, Krüger-Rainer C, Haushofer M, Kasper S

CNS drugs. 2004;18(1):49-55
Renal therapeutics: patent highlights January to June 2003.
Mucke HA

Current opinion in investigational drugs (London, England : 2000). 2003 Sep;4(9):1048-52
Localization and function of 5-HT2 receptors.
Mucke HA

IDrugs : the investigational drugs journal. 2002 Aug;5(8):776-8
Genomics and dementia--new drug targets ahead?
Mucke HA

Journal of neural transmission. Supplementum. 2002;(62):287-91
Ageing and dementia: current and future concepts.
Mucke HA

IDrugs : the investigational drugs journal. 2001 Nov;4(11):1240-3
Cognitive relapse after discontinuation of drug therapy in Alzheimer's disease: cholinesterase inhibitors versus nootropics.
Rainer M, Mucke HA, Krüger-Rainer C, Kraxberger E, Haushofer M, Jellinger KA

Journal of neural transmission (Vienna, Austria : 1996). 2001;108(11):1327-33
Recent trends in ADHD pharmacotherapy: do we need more divided attention?
Mucke HA

IDrugs : the investigational drugs journal. 2000 Sep;3(9):979-82
Apoptosis modulators: targeting cellular suicide.
Mucke HA

IDrugs : the investigational drugs journal. 2000 May;3(5):506-11
Alkaloid lead molecules for cholinergic drug development.
Mucke HA

IDrugs : the investigational drugs journal. 2000 Feb;3(2):202-7
No evidence for cognitive improvement from oral nicotinamide adenine dinucleotide (NADH) in dementia.
Rainer M, Kraxberger E, Haushofer M, Mucke HA, Jellinger KA

Journal of neural transmission (Vienna, Austria : 1996). 2000;107(12):1475-81
Alcohol-induced organic cerebral psychosyndromes: partial reversal of cognitive impairments assisted by dihydroergocristine.
Rainer M, Mucke HA, Chwatal K, Havelec L

Psychopharmacology. 1996 Oct;127(4):365-9

Hermann Mucke's Posters and Presentations (2)

An Analysis of Corneal Anesthesia Data from Patents Reveals Information not Represented in the Peer Review Literature (poster)
Hermann A. M. Mucke, Eva Mucke, Peter Mucke

World Ophthalmology Congress 2010; 06/2010

Attachment: Corneal_anesthesia_patents_Poster_P-SU-010_WOC_2010_.pdf
The REDWING-D Knowledgebase: Comprehensive Patent Informatics for Ocular Drugs and Diagnostics from 1970 Onward (poster)
Hermann A. M. Mucke, Eva Mucke, Peter Mucke

World Ophthalmology Congress 2010; 06/2010

Attachment: REDWING-D_Poster_P-SU-018_WOC_2010_.pdf

Websites

H.M. Pharma Consultancy

Join Epernicus (membership is free)

Epernicus is open to current and former research scientists.